Category: Bio & Healthcare

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced a change of listing scheduled for May 10, 2024, following the retirement of 1,119,924 common shares, reducing total issued shares to 216,929,838. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Change Listing and Total Issued Share…

Read More “[Disclosure] Celltrion (068270) – Change Listing (Retirement of Shares) / 2024-05-07” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has extended the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 107.5B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to May 31, 2024, following consultations with the client. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-04-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics reported its Q1 2024 provisional consolidated performance, recording revenue of KRW 946.9B and operating profit of KRW 221.3B, representing year-on-year increases of 31.35% and 15.41%, respectively. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final Audit…

Read More “[Disclosure] Samsung Biologics (207940) – Provisional Performance (Consolidated Financial Results) / 2024-04-24” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced its decision to acquire 436,047 common shares of treasury stock (valued at approximately KRW 75.0B) through open-market purchases to stabilize its stock price and enhance shareholder value. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury…

Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-04-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced its decision to retire 1,119,924 treasury common shares (book value of approximately KRW 176.5B) to stabilize its stock price and enhance shareholder value, scheduled for April 26, 2024. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…

Read More “[Disclosure] Celltrion (068270) – Share Retirement Decision / 2024-04-17” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice indicating that it plans to release its Q1 2024 (2024-01-01 ~ 2024-03-31) financial results on April 24, 2024. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of the Actual Disclosure Submission and…

Read More “[Disclosure] Samsung Biologics (207940) – Advance Notice of Earnings Release / 2024-04-09” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has expanded its pharmaceutical contract manufacturing agreement with Merck Sharp & Dohme (MSD), increasing the total contract value by KRW 154.6B from KRW 92.8B to KRW 247.3B following the commercialization success of the client’s product. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Sales / Supply Contract / 2024-04-04” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion disclosed that while it signed an MOU with Yesan, South Chungcheong Province for a bio-pharmaceutical plant investment, detailed plans remain unconfirmed, with a re-disclosure planned once finalized or within 6 months. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…

Read More “[Disclosure] Celltrion (068270) – Clarification on Rumors or Reports (Unconfirmed) / 2024-03-29” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has extended both the contract period and the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 91.4B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to June 30, 2024, following consultations with the client. 📊 [Key Disclosure Details & Financial…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-27” »

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has extended both the contract period and the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 154.1B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to June 30, 2024, following consultations with the client. 📊 [Key Disclosure Details & Financial…

Read More “[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-03-27” »